Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | ILLUMINATE 101: Updates and implications on colorectal cancer

Hani Babiker • 18 Oct 2019
ESMO 2019
Colorectal Cancer Gastrointestinal Cancer IMO-2125 Ipilimumab Nivolumab

Hani Babiker, MD, The University of Arizona, Tucson, AZ, discusses updates from the ILLUMINATE 101 (NCT03052205) regarding the intratumoral treatment of solid tumors with IMO-2125 and the implications of results on colorectal cancer treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Hani Babiker

3:45
Molecular target therapy in pancreatic and liver cancer
Hani Babiker • 18 Oct 2019
1:20
A promising future for drug development in gastrointestinal cancer
Hani Babiker • 29 Nov 2018
2:43
Current trials in colorectal cancer investigating panitumumab
Hani Babiker • 29 Nov 2018
1:43
Cemiplimab prospects: CRC, CSCC & HNSCC
Hani Babiker • 29 Nov 2018

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals